Fact based stock research
Bumrungrad Hospital (SET:BH)
TH0168A10Z01
How to read the free ranks
For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:
Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".
Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".
Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.
Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.
(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).
(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.
Bumrungrad Hospital stock research in summary
ANALYSIS: With an Obermatt Combined Rank of 55 (better than 55% compared with investment alternatives), Bumrungrad Hospital (Health Care Facilities, Thailand) shares have above-average financial characteristics compared with similar stocks. Shares of Bumrungrad Hospital are low in value (priced high) with a consolidated Value Rank of 37 (worse than 63% of alternatives) and show below-average growth (Growth Rank of 19) but are safely financed (Safety Rank of 100), which means low debt burdens. ...read more
RECOMMENDATION: A Combined Rank of 55, is a buy recommendation based on Bumrungrad Hospital's financial characteristics. As the company Bumrungrad Hospital's critical financial metrics exhibit below-average performance, such as low value (Obermatt Value Rank of 37) and low growth (Obermatt Growth Rank of 19), it is a somewhat questionable stock investment, where the risk of paying too much for the shares is significant, unless the company has an exceptionally bright future. In this case, good financing practices (Obermatt Safety Rank of 100) are a positive sign, because it may allow the company to weather challenging times until the hoped-for cash flows materialize. This may be true for high-tech or biotechnology companies with enough cash to sustain prolonged business development. If they own properties that only provide cash flows in the future, the stock may look excessively expensive and unattractive today. In such cases, the Obermatt Method has limited value, as it is based on facts we can observe today. If the facts lie all in the future, stock investing becomes guesswork, and this should only be a driver in a limited number of investments that account for a small fraction of a safe portfolio. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more
Latest Obermatt Ranks
Log in or sign up to see the new 360° View and Sentiment ranks.
Country | Thailand |
Industry | Health Care Facilities |
Index | SET |
Size class | Medium |
This stock has achievements: Gold Winner CEO.
20-Feb-2025. Stock data may be delayed. Log in or sign up to get the most recent research.

Analysts rarely agree on a stock’s future. So, who do you believe? Obermatt translates those collective views into a single Sentiment Rank. That plus the financial ranks give you the ultimate 360° View. Sign up to access them.

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.
Review the performance ranks of the individual metrics that form each investment strategy.
Research History: Bumrungrad Hospital
RESEARCH HISTORY | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | 19 |
![]() |
30 |
![]() |
37 |
![]() |
37 |
![]() |
GROWTH | ||||||||
GROWTH | 57 |
![]() |
61 |
![]() |
19 |
![]() |
19 |
![]() |
SAFETY | ||||||||
SAFETY | 60 |
![]() |
100 |
![]() |
100 |
![]() |
100 |
![]() |
SENTIMENT | ||||||||
SENTIMENT | 72 |
![]() |
96 |
![]() |
63 |
![]() |
new | |
360° VIEW | ||||||||
360° VIEW | 57 |
![]() |
96 |
![]() |
63 |
![]() |
new |
Combined financial peformance in Detail
ANALYSIS: With an Obermatt Combined Rank of 55 (better than 55% compared with investment alternatives), Bumrungrad Hospital (Health Care Facilities, Thailand) shares have above-average financial characteristics compared with similar stocks. Shares of Bumrungrad Hospital are low in value (priced high) with a consolidated Value Rank of 37 (worse than 63% of alternatives) and show below-average growth (Growth Rank of 19) but are safely financed (Safety Rank of 100), which means low debt burdens. ...read more
RECOMMENDATION: A Combined Rank of 55, is a buy recommendation based on Bumrungrad Hospital's financial characteristics. As the company Bumrungrad Hospital's critical financial metrics exhibit below-average performance, such as low value (Obermatt Value Rank of 37) and low growth (Obermatt Growth Rank of 19), it is a somewhat questionable stock investment, where the risk of paying too much for the shares is significant, unless the company has an exceptionally bright future. In this case, good financing practices (Obermatt Safety Rank of 100) are a positive sign, because it may allow the company to weather challenging times until the hoped-for cash flows materialize. This may be true for high-tech or biotechnology companies with enough cash to sustain prolonged business development. If they own properties that only provide cash flows in the future, the stock may look excessively expensive and unattractive today. In such cases, the Obermatt Method has limited value, as it is based on facts we can observe today. If the facts lie all in the future, stock investing becomes guesswork, and this should only be a driver in a limited number of investments that account for a small fraction of a safe portfolio. Obermatt Premium subscribers can further check the stock’s Sentiment Ranks, which also flow into the Obermatt 360° View for investors. ...read more
RESEARCH HISTORY | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
VALUE | ||||||||
VALUE | 19 |
![]() |
30 |
![]() |
37 |
![]() |
37 |
![]() |
GROWTH | ||||||||
GROWTH | 57 |
![]() |
61 |
![]() |
19 |
![]() |
19 |
![]() |
SAFETY | ||||||||
SAFETY | 60 |
![]() |
100 |
![]() |
100 |
![]() |
100 |
![]() |
COMBINED | ||||||||
COMBINED | 34 |
![]() |
88 |
![]() |
55 |
![]() |
55 |
![]() |
Value Metrics in Detail
ANALYSIS: With an Obermatt Value Rank of 37 (worse than 63% compared with alternatives), Bumrungrad Hospital shares are more expensive than the average comparable stock. The Value Rank is based on consolidating four value indicators, with half of the indicators below and half above average for Bumrungrad Hospital. Price-to-Profit (also referred to as price-earnings, P/E) is 55 which means that the stock price compared with what market professionals expect for future profits is lower than for 55% of comparable companies, indicating a good value concerning Bumrungrad Hospital's profit levels. The same is valid for Price-to-Book Capital (also referred to as market-to-book ratio) with a Price-to-Book Rank of 21, which means that the stock price is lower as regards to invested capital than for 21% of comparable investments. On the other hand, Price-to-Sales is less favorable than 73% of alternatives (only 27% of peers have an even less favorable ratio). The same is valid for dividend yield, which is lower than 22% of comparable companies, making the stock more expensive as regards to the company's expected dividend payouts. ...read more
RECOMMENDATION: The overall picture with a consolidated Value Rank of 37, is a hold recommendation based on Bumrungrad Hospital's stock price compared with the company's operational size and dividend yields. This is a puzzling picture, because it means that profits are high while dividends are low. Since the stock price is low compared with invested capital but high in respect to expected revenues, it means that the company has more invested capital than peers for generating the same amount of revenue. Since profits are higher, it could be a "cash cow" situation (using the classic Boston Consulting BCG matrix naming convention) where the company is on a downward trend, still living from the profits of past products. As the company pays low dividends, it may harbor the opinion that a turnaround is possible, and it rather invests the cash than pay it out to shareholders, thus sealing the company's fate early. Any investment optimism should only be a buy trigger once thorough research is completed. We recommend further analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks, including the 360° View, before making an investment decision, which is especially important in this case, as the financial indicators are inconclusive. ...read more
VALUE METRICS | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
PRICE VS. REVENUES (P/S) | ||||||||
PRICE VS. REVENUES (P/S) | 13 |
![]() |
14 |
![]() |
27 |
![]() |
27 |
![]() |
PRICE VS. PROFITS (P/E) | ||||||||
PRICE VS. PROFITS (P/E) | 9 |
![]() |
43 |
![]() |
55 |
![]() |
55 |
![]() |
PRICE VS. CAPITAL (Market-to-Book) | ||||||||
PRICE VS. CAPITAL (Market-to-Book) | 22 |
![]() |
15 |
![]() |
21 |
![]() |
21 |
![]() |
DIVIDEND YIELD | ||||||||
DIVIDEND YIELD | 75 |
![]() |
76 |
![]() |
78 |
![]() |
78 |
![]() |
CONSOLIDATED RANK: VALUE | ||||||||
CONSOLIDATED RANK: VALUE | 19 |
![]() |
30 |
![]() |
37 |
![]() |
37 |
![]() |
Growth Metrics in Detail
ANALYSIS: With an Obermatt Growth Rank of 19 (better than 19% compared with alternatives), Bumrungrad Hospital shows one of the most restricted growth dynamics in its industry. There is little momentum in this company. The Growth Rank is based on consolidating four value indicators, with three out of four indicators below average for Bumrungrad Hospital. Only Capital Growth has a good rank of 98, which means that currently professionals expect the company to grow its invested capital more than 25% of its competitors. The other three indicators are pointing South: Sales Growth has a rank of 4 which means that currently professionals expect the company to grow less than 96% of its competitors. Profit Growth with a rank of 25 and Stock Returns with a rank of 19 are also low (below 81% of alternative investments). ...read more
RECOMMENDATION: The overall picture with a consolidated Growth Rank of 19, is a sell recommendation for growth and momentum investors. The good news from the invested capital side is surprising. A company with disappointing revenues, profits, and disappointed shareholders typically doesn't invest above average. Overall, the growth momentum for Bumrungrad Hospital is thus negative. As it is intriguing to see that company executives are optimistic about their investment policy, it is worthwhile looking into the details of the capital investment projects. They may indicate future growth and profits and thus if accompanied by a good value, a sign of good timing to invest in the stock. While momentum is a popular investment factor, the value aspect might be the more important one, in the longer term. We recommend analyzing the stock with Obermatt’s Value, Safety, and Sentiment Ranks to arrive at a 360° View of the stock purchase case, especially since the growth performance is limited here. ...read more
GROWTH METRICS | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
REVENUE GROWTH | ||||||||
REVENUE GROWTH | 84 |
![]() |
4 |
![]() |
4 |
![]() |
4 |
![]() |
PROFIT GROWTH | ||||||||
PROFIT GROWTH | 17 |
![]() |
75 |
![]() |
25 |
![]() |
25 |
![]() |
CAPITAL GROWTH | ||||||||
CAPITAL GROWTH | 38 |
![]() |
100 |
![]() |
98 |
![]() |
98 |
![]() |
STOCK RETURNS | ||||||||
STOCK RETURNS | 55 |
![]() |
37 |
![]() |
19 |
![]() |
19 |
![]() |
CONSOLIDATED RANK: GROWTH | ||||||||
CONSOLIDATED RANK: GROWTH | 57 |
![]() |
61 |
![]() |
19 |
![]() |
19 |
![]() |
Safety Metrics in Detail
ANALYSIS: With an Obermatt Safety Rank of 100 (better than 100% compared with alternatives) for 2025, the company Bumrungrad Hospital has safe financing practices, which means that their overall debt burden is low. This doesn't mean that the business of Bumrungrad Hospital is safe, it only means that the company is on the safer side regarding possible bankruptcy, assuming that public reporting is correct. The Safety Rank is based on consolidating three financing indicators, where all three are above average for Bumrungrad Hospital. Leverage is at 98, meaning the company has a below-average debt-to-equity ratio. It has less debt than 98% of its competitors. Refinancing is at a rank of 51, meaning that the portion of the debt about to be refinanced is below average. It has less debt in the refinancing stage than 51% of its competitors. Finally, Liquidity is also good at a rank of 98, which means that the company generates more profit to service its debt than 98% of its competitors. ...read more
RECOMMENDATION: With a consolidated Safety Rank of 100 (better than 100% compared with alternatives), Bumrungrad Hospital has a financing structure that is significantly safer than that of its competitors. These three positive financing indicators signal that the company is less likely to default on its debt obligations. However, it also means that its shareholder returns will be more modest if things go well. A low safety means fewer troubles in downtimes and less upside in good times. Investors may not have a debt issue with Bumrungrad Hospital but they should also compare Obermatt’s Value, Growth, and Sentiment Ranks before making a decision. ...read more
SAFETY METRICS | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
LEVERAGE | ||||||||
LEVERAGE | 70 |
![]() |
96 |
![]() |
98 |
![]() |
98 |
![]() |
REFINANCING | ||||||||
REFINANCING | 39 |
![]() |
47 |
![]() |
51 |
![]() |
51 |
![]() |
LIQUIDITY | ||||||||
LIQUIDITY | 53 |
![]() |
98 |
![]() |
98 |
![]() |
98 |
![]() |
CONSOLIDATED RANK: SAFETY | ||||||||
CONSOLIDATED RANK: SAFETY | 60 |
![]() |
100 |
![]() |
100 |
![]() |
100 |
![]() |
Sentiment Metrics in Detail
SENTIMENT | 2022 | 2023 | 2024 | 2025 | ||||
---|---|---|---|---|---|---|---|---|
ANALYST OPINIONS | ||||||||
ANALYST OPINIONS | n/a |
![]() |
44 |
![]() |
55 |
![]() |
new | |
OPINIONS CHANGE | ||||||||
OPINIONS CHANGE | 67 |
![]() |
56 |
![]() |
36 |
![]() |
new | |
PRO HOLDINGS | ||||||||
PRO HOLDINGS | 46 |
![]() |
100 |
![]() |
61 |
![]() |
new | |
MARKET PULSE | ||||||||
MARKET PULSE | 89 |
![]() |
95 |
![]() |
94 |
![]() |
new | |
CONSOLIDATED RANK: SENTIMENT | ||||||||
CONSOLIDATED RANK: SENTIMENT | 72 |
![]() |
96 |
![]() |
63 |
![]() |
new |
Free stock analysis by the purely fact based Obermatt Method for Bumrungrad Hospital from February 20, 2025.
Obermatt Portfolio Performance
We’re so convinced about our free research, that we buy our stock tips.
See the performance of the Obermatt portfolio.